There are 2185 resources available
713MO - Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial
Presenter: Oliver Klein
Session: Mini oral session 1: Gynaecological cancers
Resources:
Abstract
504O - IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort
Presenter: Christelle de la Fouchardiere
Session: Proffered paper session 1: GI tumours, lower
Resources:
Abstract
LBA22 - Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
Presenter: Xichun Hu
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
1694MO - Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER
Presenter: David Braun
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
450MO - Characterization of tumor-infiltrating lymphocytes and tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Mini oral session: CNS tumours
Resources:
Abstract
814MO - Molecular biology study of primary immuno-privileged lymphomas
Presenter: Chen Zhang
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
LBA32 - A randomized, phase II, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: Safety, efficacy and dose optimization (PRESERVE-004/GOG-3081)
Presenter: Joyce Barlin
Session: Mini oral session 1: Gynaecological cancers
Resources:
Abstract
345MO - IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study
Presenter: Christina Teng
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract
815MO - A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety
Presenter: Jia-Dai Xu
Session: Mini oral session 2: Haematological malignancies
Resources:
Abstract
346MO - Trastuzumab deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies
Presenter: Lana Elu
Session: Mini oral session 1: Breast cancer, metastatic
Resources:
Abstract